Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

No longer available 1Completed 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Melanoma 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Carcinoma, Hepatocellular 2Solid Cancers 1Liver Cirrhosis 1Hepatitis D 1Hepatitis B 1Fibrosis 1Esophageal and Gastric Varices 1Carcinoma, Renal Cell 1

Interventions

Sorafenib 79pembrolizumab 37Bevacizumab 36Nivolumab 33lenvatinib 30atezolizumab 24durvalumab 17Oxaliplatin 12Ipilimumab 12regorafenib 9Capecitabine 9tremelimumab 8Injections 8Doxorubicin 8tislelizumab 7sintilimab 7Fluorouracil 7cabozantinib 6budigalimab 6brivanib 6Ramucirumab 6toripalimab 5Gemcitabine 5Everolimus 5Cyclophosphamide 5ADI PEG20 5fludarabine 4Sunitinib 4Leucovorin 4E-7386 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Hepatocellular × peginterferon alfa-2a × Clear all
NCT05683548 2025-02-17

RCAP

Replicor Inc.

No longer available
Gastrointestinal

Hepatitis D, Esophageal and Gastric Varices, Fibrosis, Hepatitis B, Carcinoma, Hepatocellular, Liver Cirrhosis

NCT02576964 2016-11-02

A Study of Capecitabine (Xeloda) and Peginterferon Alfa-2a (Pegasys) in Treatment-Naive Participants With Advanced Liver Cancer

Hoffmann-La Roche

Phase 2 Completed
16 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡